Third response in concurrent BTKi Cohort of azer-cel Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The second Follicular Lymphoma patient in this cohort has achieved a partial response after previously progressing on BTKi therapy. Both patients treated in this cohort have shown a response to the concurrent treatment with azer-cel and BTKi. The trial continues to enroll patients across multiple sites in the U.S. and Australia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- $11.1 Million Placement Completed to Advance azer-cel
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- First Complete Response in Concurrent BTKi azer-cel Cohort
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study
Later from Imugene
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notification of cessation of securities - IMU
- Final Director's Interest Notice - LC
- Expiry Of Listed Options
- Letter To Shareholders
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene